Yabing CAO 照片

Yabing CAO

客座教授

所属大学: 澳门大学

所属学院: 健康科学学院

邮箱:
sumscaoyabing@hotmal.com

个人主页:
https://fhs.um.edu.mo/en/staff/yabing-cao/

个人简介

Education Ph.D. candidate of Medical Oncology Sun Yat-sen University, Guangzhou, China Master of Medical Oncology Sun Yat-sen University, Guangzhou, China Bachelor of Medicine Henan Medical University, Zhengzhou, China Academic and Professional Experience 2016 to present Adjunct Associate Professor, Faculty of Health Sciences, University of Macau 2010 to present Attending Physician, Medical Oncologist, Department of Oncology, Kiang Wu Hospital

近期论文

Representative Publications Huang, H., Li, X., Zhu, J., Ye, S., Zhang, H., Wang, W., Wu, X., Peng, J., Xu, B., Lin, Y., Cao, Y., Li, H., Lin, S., Liu, Q. & Lin, T. (2014). Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA 312, 2521-30. (IF: 30.3) Cao, Y., Xiao, G., Qiu, X., Ye, S. & Lin, T. (2014). Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients. PLoS One 9, e114008. (IF: 3.5) Xiao, G., Cao, Y., Qiu, X., Wang, W. & Wang, Y. (2013). Influence of gender and age on the survival of patients with nasopharyngeal carcinoma. BMC Cancer 13, 226. (IF: 3.3) Huang, Y., Ye, S., Cao, Y., Li, Z., Huang, J., Huang, H., Cai, M., Luo, R. & Lin, T. (2012). Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients. Scientific World Journal 2012, 897178.2. (IF:3.5) Cao, Y., Lan, Y., Qian, J., Zheng, Y., Hong, S., Li, H., Wang, M., Kwak, L. W., Lin, D., Yang, J. & Yi, Q. (2011). Targeting cell surface beta2 -microglobulin by pentameric IgM antibodies. Br J Haematol 154, 111-21. (IF: 4.9) Zhai, L., Guo, C., Cao, Y., Xiao, J., Fu, X., Huang, J., Huang, H., Guan, Z. & Lin, T. (2010). Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin’s lymphoma: single center, 15-year experience. Int J Hematol 91, 78-86. (IF: 1.6) Yang, J., Cao, Y., Hong, S., Li, H., Qian, J., Kwak, L. W. & Yi, Q. (2009). Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Clin Cancer Res 15, 951-9. (IF: 8.1)